PSIVIDA CEO TO PRESENT AT 15TH ANNUAL BIOCEO & INVESTOR CONFERENCE FEBRUARY 12

Watertown, Mass., (February 5, 2013) -- (BUSINESS WIRE) – pSivida Corp. (NASDAQ:PSDV; ASX:PVA), an emerging specialty pharmaceutical company and leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr. Paul Ashton, will present at the 15th Annual BioCEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York, Monday and Tuesday, February 11 and 12. Dr. Ashton will make his presentation on Tuesday, February 12 at 1 p.m. US EST. A webcast of the presentation will be available at the company's website: www.psivida.com. There will be a webcast replay available one hour after the conclusion of Dr. Ashton's presentation that day and it will be available until May 12, 2013.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drugs designed to be released at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. Two FDA-approved products, Vitrasert™ and Retisert™ are licensed to Bausch & Lomb. The company has licensed ILUVIEN® for DME to Alimera Sciences and that product has received marketing authorization in Austria, France, Germany, Portugal, Spain and the UK. pSivida has clinical trials ongoing for the treatment of posterior uveitis and glaucoma and hypertension. Other technologies under development by pSivida include protein and antibody delivery systems in early clinical stages.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: Alimera's ability to finance, achieve additional marketing approvals, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's resubmission of its NDA for ILUVIEN for DME and its ability to obtain regulatory approval for, and if approved, to finance, successfully commercialize and achieve market acceptance of, and generate revenues to

pSivida from, ILUVIEN for DME in the U.S.; financing and success of Phase III posterior uveitis trials including efficacy, side effects and risk/benefit profile of the posterior uveitis micro-insert; initiation, financing and success of Latanoprost Product Phase II trials and exercise by Pfizer of its option; development of products using Tethadur and BioSilicon; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; adverse side effects; ability to attain profitability; ability to obtain additional capital; further impairment of intangible assets; fluctuations in operating results; decline in royalty revenues; ability to, and to find partners to, develop and market products; termination of license agreements; competition and other developments affecting sales of products; market acceptance; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; possible influence by Pfizer; absence of dividends; and other factors described in our filings with the SEC. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contact:

Brian Leedman
Vice President, Investor Relations
pSivida Corp.
+61 (0) 41 228 1780
brianl@psivida.com

In US:
Beverly Jedynak
President
Martin E. Janis & Company, Inc.,
Tel: +1 (312) 943 1123
bjedynak@janispr.com